SMFM Statement on Supreme Court Decision to Uphold Access to Medication Abortion


The Supreme Court’s ruling yesterday ensures that mifepristone, a critical medication for reproductive health and abortion care, remains available to patients and that clinicians can continue to provide evidence-based care without additional undue restrictions. 

“This decision is a welcomed victory for our members and the patients they serve,” said Dr. Cynthia Gyamfi-Bannerman, President of the Society for Maternal-Fetal Medicine (SMFM). “As highly trained experts in high-risk pregnancy, our priority is to deliver the best possible care for patients facing complicated pregnancies with unique medical needs. This ruling ensures that mifepristone remains available and allows us to continue to provide safe, effective, and compassionate care.”  

Every person deserves access to the full spectrum of reproductive health care, including abortion care. SMFM is dedicated to ensuring every person gets the care they need and the outcome that is best for them and their pregnancy. 


About SMFM
SMFM The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for obstetricians who have additional training in high-risk, complicated pregnancies. SMFM represents more than 7,000 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to reduce disparities and optimize the health of high-risk pregnant people and their families. SMFM and its members are dedicated to optimizing maternal and fetal outcomes and assuring medically appropriate treatment options are available to all patients.

For media interviews, contact: